<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02200822</url>
  </required_header>
  <id_info>
    <org_study_id>ZOL-STOP-CRT</org_study_id>
    <nct_id>NCT02200822</nct_id>
  </id_info>
  <brief_title>Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients</brief_title>
  <acronym>STOP-CRT</acronym>
  <official_title>Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding Patients to Cardiac Resynchronization Therapy: the STOP-CRT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate that in patients with
      recuperated/normalized left ventricular function, defined as an ejection fraction (EF) ≥ 50%,
      after implantation of cardiac resynchronization therapy, device treatment is sufficient and
      neurohumoral blocker therapy can safely be withdrawn
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a &gt; 15% increase in left ventricular end systolic volume</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Incidence of HF related hospitalizations defined as admission to hospital / presentation to emergency room with need for parental therapy</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 max change</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>&gt;15% increase in left ventricular end systolic volume</measure>
    <time_frame>6 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>&gt; 15% decrease in left ventricular ejection fraction</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>mean blood pressure change</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>HF symptoms change (dyspnea visual analogue scale (VAS), New York Heart Association (NYHA) class, questionnaire &quot;Minnesota living with Heart Failure&quot;)</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>incidence of heart rhythm events (sustained ventricular tachycardia (VT), atrial fibrillation, ventricular fibrillation)</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>heart rate variability</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>urinary catecholamine concentration</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in myocardial contractility (force frequence relationship, left ventricular pre-ejection time, iso-volumetric contraction time, dP/dt)</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in diastolic filling pattern</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>plasma concentrations of plasma renin activity and aldosterone</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Heart Failure (HF)</condition>
  <arm_group>
    <arm_group_label>non-intervention arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>continuation of neurohumoral blocker therapy based on maximum tolerated guideline recommended dose (this group is the control arm for as well withdrawal of beta blocker therapy as withdrawal of RAAS blocker therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>withdrawal of beta blockers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention arm with systematic withdrawal of beta blocker therapy at a reverse sequence of guideline recommended uptitration.
(this group is the experimental arm for beta blocker withdrawal. This group receives no intervention with regards to the withdrawal of RAAS blockade). Per 2 weeks:
bisoprolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop
metoprolol: 200 mg/d → 100 mg/d → 50 mg/d → 25 mg/d → stop
nebivolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop
carvedilol: 50 mg bid → 25 mg bid → 12,5 mg bid → 6,25 mg bid → stop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>withdrawal of RAAS blockers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intervention arm with systematic withdrawal of spironolactone followed by withdrawal of ACE-I/ARB at a reverse sequence of guideline recommended uptitration (this group receives no intervention regarding the withdrawal of beta blockers. This group is the experimental arm for withdrawal of RAAS blockers)
first spironolactone/eplerenone: per two weeks: 25 mg/d→12,5 mg/d → stop
after 2 weeks stop spironolactone/eplerenone start withdrawal of ACE-I/ARB per two weeks:
captopril: 50 mg tid→25 mg tid→12,5 mg tid→6,25 mg tid→stop
enalapril: 10 mg bid→5 mg bid→2,5 mg bid→1,25 mg bid→stop
lisinopril: 20 mg/d→10 mg/d→5 mg/d→2,5 mg/d→stop
ramipril: 10 mg/d→5 mg/d→2,5 mg/d→1,25 mg/d→stop
candesartan: 32 mg/d→16 mg/d→8 mg/d→4 m/d→stop
valsartan: 160 mg bid→80 mg bid→40 mg bid→20 mg bid→stop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>withdrawal of RAAS - and beta blockers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intervention arm with systematic withdrawal of spironolactone, secondly ACE-I/ARB and finally beta blockers. (this group is the experimental group for both study interventions (withdrawal of beta blockers and RAAS blockers)
First: spironolactone/eplerenone cfr reduction schedule supra
After 2 weeks of stop spironolactone withdrawal of ACE-I or ARB cfr reduction schedule supra
After 2 weeks of stop ACE-I/ARB withdrawal of beta blocker cfr reduction schedule supra</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beta blockers</intervention_name>
    <arm_group_label>withdrawal of beta blockers</arm_group_label>
    <arm_group_label>withdrawal of RAAS - and beta blockers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAAS blockers</intervention_name>
    <description>RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)</description>
    <arm_group_label>withdrawal of RAAS blockers</arm_group_label>
    <arm_group_label>withdrawal of RAAS - and beta blockers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years

          -  CRT implantation

               -  based on class I recommendations of ESC (European society of CArdiology)
                  guidelines:

               -  Left bundle branch block (LBBB) with QRS duration &gt;150 ms and left ventricular
                  ejection fraction (LVEF) ≤35% who remained NYHA functional class II, III and
                  ambulatory IV despite adequate medical treatment

               -  LBBB with QRS duration 120-150 ms and LVEF ≤ 35% who remain in NYHA functional
                  class II, III and ambulatory IV despite adequate medical treatment

          -  At the moment of inclusion: ≥ 6 months after implantation

          -  At the moment of inclusion: normalised LVEF (≥ 50%), LVIDD/BSA (left ventricular
             internal diastolic diameter indexed to body surface area) ≤3.2 cm/m²(woman) en ≤3.1
             cm/m² (men) or LVDV/BSA (left ventricular diastolic volume indexed to body surface
             area) ≤75 ml/m² (women) or ≤75 ml/m² (men)

          -  euvolemic clinical state and functioning in NYHA class I

        Exclusion Criteria:

          -  contraindication for withdrawal of ACE-I/ARB such as diabetic nephropathy and
             proteinuria &gt; 1g / 24 h

          -  severe ventricular arrythmia (sustained VT or ventricular fibrillation) occuring at
             the time LV function was normalized

          -  ischemic cardiomyopathy with evidence of scarring (scarring on MRI or severe
             hypokinesia/akinesia in &gt;1 LV wall segment on echocardiography)

          -  known severe coronary atherosclerosis (stenosis ≥ 80%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra Nijst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petra Nijst, MD</last_name>
    <phone>3289761525</phone>
    <email>nijst.petra@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wilfried Mullens, MD, PhD</last_name>
    <phone>3289327110</phone>
    <email>wilfried.mullens@zol.Be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Nijst, MD</last_name>
      <phone>3289761525</phone>
      <email>nijst.petra@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Wilfried Mullens, MD, PhD</last_name>
      <phone>3289327110</phone>
      <email>wilfried.mullens@zol.Be</email>
    </contact_backup>
    <investigator>
      <last_name>Petra Nijst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederik Verbrugge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Dupont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wilfried Mullens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2014</study_first_submitted>
  <study_first_submitted_qc>July 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2014</study_first_posted>
  <last_update_submitted>July 24, 2014</last_update_submitted>
  <last_update_submitted_qc>July 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Wilfried Mullens, MD PhD</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>neurohumoral blocker therapy</keyword>
  <keyword>renin-angiotensin-aldosterone system (RAAS)</keyword>
  <keyword>RAAS-blocker</keyword>
  <keyword>beta blocker</keyword>
  <keyword>spironolactone</keyword>
  <keyword>angiotensin converting enzyme inhibitor (ACE-I)</keyword>
  <keyword>angiotensin receptor blocker (ARB)</keyword>
  <keyword>cardiac resynchronization therapy (CRT)</keyword>
  <keyword>heart failure</keyword>
  <keyword>dyssynchrony</keyword>
  <keyword>left bundle branch block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

